Ribociclib
Back to searchMolecule Structure
Scientific Name
Ribociclib
Description of the Drug
Ribociclib is a kinase inhibitor used to treat HR+, HER2- advanced or metastatic breast cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11730
http://www.drugbank.ca/drugs/DB11730
Brand Name(s)
Not Available
Company Owner(s)
Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Cyclin-dependent kinase 4 | SINGLE PROTEIN | INHIBITOR | CHEMBL331 |
Cyclin-dependent kinase 6 | SINGLE PROTEIN | INHIBITOR | CHEMBL2508 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL302310 | ||
PharmGKB | PA166153470 | ||
Human Metabolome Database | HMDB0257211 | ||
DrugBank | DB11730 | ||
PubChem: Thomson Pharma | 87793394 | ||
PubChem | 44631912 | ||
LINCS | LSM-45221 | ||
Nikkaji | J3.462.341D | ||
PDBe | 6ZZ | ||
BindingDB | 148264 | ||
DrugCentral | 5218 | ||
ChemicalBook | CB32677045 | ||
Guide to Pharmacology | 7383 | ||
rxnorm | RIBOCICLIB | RIBOCICLIB SUCCINATE | KISQALI |
ZINC | ZINC000072316335 |